📊 UNCY Key Takeaways
Is Unicycive Therapeutics, Inc. (UNCY) a Good Investment?
Unicycive is a pre-commercial biotech with minimal revenue ($675K, declining -29% YoY) and severe cash burn ($6.2M quarterly operating loss) against only $37.4M in remaining cash, providing roughly 6 quarters of runway. The company exhibits extreme unprofitability (net margin -1899.7%) with no visible path to profitability or revenue acceleration, despite a strengthened balance sheet with zero debt.
Why Buy Unicycive Therapeutics, Inc. Stock? UNCY Key Strengths
- No debt and strong liquidity position with current ratio of 2.40x reduces near-term refinancing risk
- Substantial cash reserves of $37.4M provide clinical development runway
- EPS improved 70.4% YoY, showing some operational progress despite absolute losses
UNCY Stock Risks: Unicycive Therapeutics, Inc. Investment Risks
- Accelerating cash burn of $6.2M quarterly with only ~6 quarters of runway remaining
- Severe revenue decline of -29% YoY indicates loss of pipeline momentum or failed commercialization
- Extreme negative profitability metrics (operating margin -1249.9%, net margin -1899.7%) with no clear path to breakeven
- Minimal revenue generation ($675K annually) inconsistent with commercial-stage biotech
- Zero insider Form 4 filings in past 90 days suggests lack of insider confidence
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway (critical survival metric)
- Revenue growth trend reversal from current -29% YoY decline
- Operating loss magnitude and trajectory toward profitability
- Clinical trial advancement or regulatory milestone achievements (not in financial data)
Unicycive Therapeutics, Inc. (UNCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.40x current ratio provides a solid financial cushion.
UNCY Profit Margin, ROE & Profitability Analysis
UNCY vs Healthcare Sector: How Unicycive Therapeutics, Inc. Compares
How Unicycive Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Unicycive Therapeutics, Inc. Stock Overvalued? UNCY Valuation Analysis 2026
Based on fundamental analysis, Unicycive Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Unicycive Therapeutics, Inc. Balance Sheet: UNCY Debt, Cash & Liquidity
UNCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Unicycive Therapeutics, Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-5.65 indicates the company is currently unprofitable.
UNCY Revenue Growth, EPS Growth & YoY Performance
UNCY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $675.0K | -$3.8M | $-0.05 |
| Q2 2024 | $675.0K | -$3.8M | $-0.15 |
| Q1 2024 | $675.0K | -$14.6M | $-0.61 |
| Q3 2023 | $675.0K | -$3.5M | $-0.13 |
| Q2 2023 | $675.0K | -$3.5M | $-0.24 |
| Q1 2023 | $675.0K | -$3.5M | $-0.24 |
| Q3 2022 | $951.0K | -$964.0K | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Unicycive Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
UNCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Unicycive Therapeutics, Inc. (CIK: 0001766140)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UNCY
What is the AI rating for UNCY?
Unicycive Therapeutics, Inc. (UNCY) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UNCY's key strengths?
Claude: No debt and strong liquidity position with current ratio of 2.40x reduces near-term refinancing risk. Substantial cash reserves of $37.4M provide clinical development runway.
What are the risks of investing in UNCY?
Claude: Accelerating cash burn of $6.2M quarterly with only ~6 quarters of runway remaining. Severe revenue decline of -29% YoY indicates loss of pipeline momentum or failed commercialization.
What is UNCY's revenue and growth?
Unicycive Therapeutics, Inc. reported revenue of $675.0K.
Does UNCY pay dividends?
Unicycive Therapeutics, Inc. pays dividends, with $1.1M distributed to shareholders in the trailing twelve months.
Where can I find UNCY SEC filings?
Official SEC filings for Unicycive Therapeutics, Inc. (CIK: 0001766140) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UNCY's EPS?
Unicycive Therapeutics, Inc. has a diluted EPS of $-0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UNCY a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Unicycive Therapeutics, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is UNCY stock overvalued or undervalued?
Valuation metrics for UNCY: ROE of -34.0% (sector avg: 15%), net margin of -1,899.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy UNCY stock in 2026?
Our dual AI analysis gives Unicycive Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is UNCY's free cash flow?
Unicycive Therapeutics, Inc.'s operating cash flow is $-6.2M, with capital expenditures of $8.0K. FCF margin is -925.8%.
How does UNCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,899.7% (avg: 12%), ROE -34.0% (avg: 15%), current ratio 2.40 (avg: 2).